Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This review synthesizes clinical evidence for Belapectin, a Galectin-3 inhibitor, focusing on its ability to prevent esophageal varices in patients with MASH cirrhosis and portal hypertension as demonstrated in the NAVIGATE trial.
This review synthesizes clinical evidence for belapectin in MASH cirrhosis, focusing on its efficacy in preventing esophageal varices as demonstrated in the NAVIGATE trial and early phase 2b data.
This review synthesizes clinical evidence on belapectin, a galectin-3 inhibitor, highlighting its potential to reduce the incidence of esophageal varices in patients with MASH-related cirrhosis and portal hypertension, particularly at the 2